NSE: NATCOPHARM · 16 November 2026
- NATCO Pharma Ltd. shares advanced 2.25% today, closing at ₹828.65 after moving within a intraday range of ₹809.15 to ₹881.80.
- Natco Pharma Limited submitted its financial results for the period ended September 30, 2026, to the exchange. Alongside the earnings update, the company declared a second interim dividend of ₹1.25 per share for the financial year 2026-27, establishing November 19, 2026, as the record date.
- Trading volume was 7.14 times the 20-day average daily volume.
Why is NATCO Pharma share price rising on 16 November 2026?
NATCO Pharma Ltd. shares advanced 2.25% today, closing at ₹828.65 after moving within a intraday range of ₹809.15 to ₹881.80.
The broader market showed positive momentum as the Nifty benchmark rose 0.58%, whereas the relevant sector benchmark, Nifty Pharma, declined by 1.53%. NATCO Pharma bucked the weak sectoral trend, outperforming pharmaceutical peers on the back of heavier cash-market participation.
Recent fundamental developments provide broader operational context for the stock. The company recently announced its financial results for the quarter ended September 30, 2026, alongside the declaration of a second interim dividend of ₹1.25 per share, with the record date set for November 19, 2026. While these corporate updates frame the current operational backdrop, no single fresh catalyst was explicitly linked to today's intraday bounce.
44.91 lakh shares traded by 16 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 6.29 lakh shares (7.14 times). The five-day average daily volume was 11.10 lakh shares. Separately, the NSE report for 16 November 2026 showed 11.71 lakh shares delivered, representing 26.08% of that day’s traded volume. The same report recorded 157,453 trades.
The stock moved higher by 2.25% amid exceptionally high trading volume—7.14 times the 20-day average—while diverging positively from a weaker Nifty Pharma sector. However, no direct single catalyst from today links explicitly to the move, making it largely a function of stock-specific volume and positioning.
Latest Company Developments
Natco Pharma Limited submitted its financial results for the period ended September 30, 2026, to the exchange. Alongside the earnings update, the company declared a second interim dividend of ₹1.25 per share for the financial year 2026-27, establishing November 19, 2026, as the record date.
Quarterly financial performance and capital return announcements are direct indicators of profitability and cash distribution to shareholders.
The Fund-Raising Committee of Natco Pharma approved the allotment of 17,058,082 equity shares pursuant to its previously announced rights issue. This followed the close of the issue period on October 22, 2026, which offered shares at ₹750 each in a 2:21 ratio.
The capital raise alters the company's equity base and infuses fresh funds, impacting overall liquidity and share dilution.
Natco Pharma announced the commercial launch of Carboplatin Injection, a generic equivalent to Paraplatin, in the United States market. The press release outlined the introduction of this key oncology injectable product in a regulated market.
New product launches in the regulated U.S. market contribute to the company's export revenue growth and strengthen its oncology portfolio.
Natco Pharma Shares Rally 9% Despite Weak Q2 Results; Details Inside NDTV Profit
Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026 and declaration of 2nd Interim Dividend for FY 2026-27.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 7.01% on 23 October 2026. This compares with 2.25% on 30 September 2026, a change of +4.76 percentage points.
The filing reported 24 MF/UTI holders.
What to Watch Next
- Stock price reaction leading up to the interim dividend record date on November 19, 2026
- Execution and revenue contribution from recent U.S. product launches such as Carboplatin Injection
- Sustained delivery volume relative to the 20-day average of 7.14x turnover
- Integration and market response following the recent rights issue share allotment
More NATCO Pharma news and dated analysis →
Frequently Asked Questions
What is the latest NATCO Pharma company news?
Natco Pharma Limited submitted its financial results for the period ended September 30, 2026, to the exchange. Alongside the earnings update, the company declared a second interim dividend of ₹1.25 per share for the financial year 2026-27, establishing November 19, 2026, as the record date.
How strong was NATCO Pharma’s trading volume?
44.91 lakh shares traded, 7.14 times the 20-day average daily volume. The price and volume data are dated 16 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 23 October 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.
